PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics

Alia Ghoneum; Neveen Said

doi:10.3390/cancers11070949

PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics

Cancers (Basel). 2019 Jul 5;11(7):949. doi: 10.3390/cancers11070949.

Authors

Alia Ghoneum¹, Neveen Said²

Affiliations

¹ Departments of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA.
² Departments of Cancer Biology, Pathology, and Urology, Wake Forest University School of Medicine, Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC 27157, USA. nsaid@wakehealth.edu.

Abstract

Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.

Keywords: NFκB; PI3K-AKT-mTOR; ovarian cancer; therapy.

Publication types

Review

Abstract

Publication types

Grants and funding